Table 3 Univariate and multivariate analysis of overall survival
Clinical parameter | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
n (% ) | Median (months)# | P value | HR (95% CI) | P value | |
Age | 0, 248 | ||||
< 65 | 38 (82, 6%) | 70, 1% | |||
≥ 65 | 8 (17, 4%) | 75, 0% | |||
Histopathologic cell type | 0, 043* | NS | NS | ||
Serous | 24 (52, 2%) | 62, 5% | |||
Others | 22 (47, 8%) | 80, 8% | |||
Residual tumor size | 0, 134 | ||||
<1 cm | 19 (41, 3%) | 81, 1% | |||
> 1 cm | 27 (58, 7%) | 55, 9% | |||
Performance status (ECOG) | 0, 276 | ||||
0-1 | 43 (93, 5%) | 71, 2% | |||
2 | 3 (6, 5%) | 66, 6% | |||
Tumor grade | 0, 498 | ||||
G1, G2 | 21 (45, 6%) | 32, 6 | |||
G3, unknown | 25 (54, 4%) | 40, 4 | |||
Sensitivity to first-line chemotherapy | <0, 0001* | 16, 84 (5, 07-55, 98) | <0, 0001* | ||
Resistant (<6 months) | 26 (35, 1%) | 21, 7% | |||
Sensitive (>6 months) | 48 (64, 9%) | 93, 4% | |||
E-cadherin membranous | 0, 472 | ||||
Negative | 7 (15, 2%) | 50, 0 | |||
Positive | 39 (84, 8%) | 35, 7 | |||
E-cadherin cytoplasmic | 1 (2, 2%) | - | - | ||
Negative | 45 (97, 8%) | ||||
Positive | |||||
β-catenin membranous | 0, 039* | NS | NS | ||
Normal | 21 (45, 6%) | 22, 2 | |||
Decreased | 25 (54, 4%) | 62, 2 | |||
β-catenin cytoplasmic | 0, 916 | ||||
Negative | 27 (58, 7%) | 32, 6 | |||
Positive | 19 (41, 3%) | 40, 1 | |||
β-catenin nuclear | - | - | |||
Negative | 46 (100, 0%) | ||||
Positive | 0 (0, 0%) | ||||
WNT-1 | 0, 846 | ||||
Normal | 31 (67, 4%) | 33, 7 | |||
Decreased | 15 (32, 6%) | 40, 5 | |||